EMPOWER CLINICS INC announce that its subsidiary EPW Curesearch LLC ("EPWC") has signed another Research Services Agreement ("Research Agreement") with a leading physician and researcher who will act as a Principal Investigator (the "PI") supporting the provision of Pharmaceutical Research and Clinical Trials Services (the "Services") of the first site in Dallas, TX. The Company also participated in the Association of Clinical Research Professionals (ACRP) annual conference in Dallas, TXApril 28 - May 1, 2023. With more than 13,000 members, the Association of Clinical Research Professionals (ACRP) is the only non-profit organization solely dedicated to representing, supporting, and advocating for clinical research professionals.

The addition of one more PI brings the active count of seasoned researchers to four and paves the way to conducting multiple research projects across a variety of specialties and disease states. PI's are practicing medical doctors who are specialists or internists with previous research and clinical trials experience that are integral to the success of the clinical trial process, including the establishment of Empower as a Site Management Organization ("SMO"). In order for shareholders to better understand both the process and the critical role played by Empower within it, have provided the following outline: Big Pharmaceutical companies conduct research and clinical trials on numerous disease states (the "Sponsor"); Successful new drugs that get FDA or CE approval are potentially worth billions to the Sponsor; Sponsors typically outsource the management of research trials to Contract Research Organizations ("CRO"); Specialized physicians referred to as Principal Investigators (PI's) become researchers at sites for the purpose of enrolling patients and supporting the trial; Empower and EPWC as an SMO enters into contracts with PI's, which in this case, is a large medical center with multiple PI's under contract; Empower and EPWC as the SMO liaise with the CRO and the Sponsor to create a three-way contract for research and clinical trials.

Once the trial commences: Patients enroll in a trial; They are seen by the PI on regular intervals; The PI gathers the required data; and The data is assembled, de-identified and provided to the CRO and Sponsor. As the SMO, Empower and EPWC oversee the process of day-to-day patient management, site management, technology management and general oversight of the trial process. Each month Empower and EPWC as the SMO submit a detailed invoice to the CRO for patient management services and participation in a trial.

KEY METRICS OF THE SITE MANAGEMENT ORGANIZATION: The key metrics that impact the success of each trial for the SMO are: Patient enrolment per trial; Patient stickiness per trial; The term, length, and possible extension per trial; and The number of active trials under management. As an SMO, Empower and EPWC expect to have multiple PI's on multiple trials. Successful new drugs have a significant anticipated value to Sponsors, the Sponsors are motivated and incentivized to keep trials on track.

Contracts come with extremely detailed payout schedules for every single touchpoint and element of every project. Expenses and payouts follow a generally standardized formula: PI's are typically paid a percentage of the contract value; and Empower as the SMO operates with a variable cost model and far superior cash flow control. Empower limits and eliminates capital expenses related to: Opening a clinic; Buying a clinic; and Entering into long-term leases.

Empower anticipates much improved cash flow economics each month and quarter, which are expected to improve as greater scale is achieved.